WNT5A is a current target of interest for treatment of several lung diseases in which there is aberrant expression of this ligand including: chronic obstructive pulmonary disease (COPD)/emphysema, idiopathic pulmonary arterial hypertension (IPAH), bronchopulmonary dysplasia (BPD), and interstitial pneumonia (UIP) (Vuga et al., 2009; Baarsma et al., 2017; Yuan et al., 2019; Li et al., 2020; Sucre et al., 2020; Vladar and Königshoff, 2020). Here, WNT5A is linked to pulmonary emphysema.